VIA
GRCL

Vident Investment Advisory’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Vident Investment Advisory’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,681
Closed -$38.4K – 1316
2022
Q4 		$38.4K Hold
16,681
– – ﹤0.01% 1160
2022
Q3 		$54K Sell
16,681
-3,280
-16% -$10.7K ﹤0.01% 1095
2022
Q2 		$110K Hold
19,961
– – ﹤0.01% 1187
2022
Q1 		$47K Buy
19,961
+7,331
+58% +$25K ﹤0.01% 1249
2021
Q4 		$76K Sell
12,630
-3,838
-23% -$36.9K ﹤0.01% 1193
2021
Q3 		$228K Buy
+16,468
New +$194K 0.01% 1061

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vident Investment Advisory's GRCL Position: Q1 2023 in Review

Vident Investment Advisory sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2023, closing a stake of 16,681 shares — an estimated $38.4K sold.

Vident Investment Advisory first reported a position in GRCL in Q3 2021 and held it in 6 quarters. The position peaked at $228K in Q3 2021. 33 funds tracked by Wall St. Rank hold GRCL as of Q1 2023.

  • Vident Investment Advisory reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 16,681 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2023, an estimated $38.4K.
  • Vident Investment Advisory first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2021 and held it in 6 quarters.
  • Vident Investment Advisory's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $228K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2023.

Based on Vident Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.